Muscle Injury: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2019–2025)

“GervanoRA’s Market Estimation report “Muscle Injury: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2019–2025)” analyzed the current and upcoming opportunities in the Muscle Injury area by assessing the drug market, covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Muscle Injury industry. The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analysis and Clinical Trials summary to provide in depth insights about the market dynamics and ongoing R&D in the Muscle Injury area. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development. The report evaluated the current market scenario by estimating the market value with respect to Muscle Injury Drug Class, Route of Administration and Age Group. Report primarily focuses on the patent analysis of the key marketed and pipeline drugs to provide a brief understanding about the market opportunities in the Muscle Injury competitive environment. We have also prognosticated the Muscle Injury market share in 11 Major Markets to aid our clients with the commercial and economic opportunities in these geographies.
Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on
• Epidemiology and Epidemiology forecast 2019 – 2025
• Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
• Estimated Pipeline Drug Approval Timelines
• Clinical Trials Summary
• Current and Future Competitive Landscape
• Key Company Profiles with SWOT Analysis
• Emerging Company Profiles with Opportunity Assessments
• Pipeline Drug Descriptions along with Development milestones (Past and Future)
• University Pipeline Molecules & In-Licensing/Out Licensing Opportunities.”

“TABLE OF CONTENTS
1. INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. METHODOLOGY
1.3. UPCOMING AND OTHER AVAILABLE REPORTS
1.4. ABOUT US: GERVANORA DATA SERVICES
2. EXECUTIVE SUMMARY
2.1. MARKET SNAPSHOT, 2019-2025
2.2. KEY EVENTS IN MUSCLE INJURY MARKET, 2015-2030
2.3. PRODUCT LIFE CYCLE MANAGEMENT (LCM) STRATEGIES
2.4. KEY MAJOR FINDINGS
2.4.1. DRIVERS
2.4.2. RESTRAINTS
2.4.1. UNMET NEEDS AND OPPORTUNITIES
3. DISEASE OVERVIEW
3.1. DISEASE DEFINITION & SYMPTOMS
3.1.1. CLINICAL MANIFESTATIONS
3.1.2. PATHOGENESIS
3.2. DISEASE CAUSE AND CLASSIFICATION
3.3. DISEASE DIAGNOSIS
3.4. TREATMENT ALGORITHM AND GUIDELINES
3.5. EPIDEMIOLOGY AND DISEASE BURDEN
3.6. EPIDEMIOLOGY FORECAST
3.6.1. FORECAST METHODOLOGY AND ASSUMPTION
3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST
4. MARKET OVERVIEW
4.1. GOVERNMENT REGULATORY DYNAMICS AND IMPACT
4.2. PRICING AND REIMBURSEMENT
4.3. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)
4.4. NEW DRUG APPROVALS (US FDA) SINCE 2010
4.5. NEW DRUG APPROVALS (EMA) SINCE 2010
4.6. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)
5. PIPELINE ANALYSIS AND ESTIMATED APPROVAL TIMELINE
5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
5.1.1. PRE-REGISTRATION (FILED) MOLECULES
5.1.2. PHASE 3 MOLECULES
5.1.3. PHASE 2 MOLECULES
5.1.4. PHASE 1 MOLECULES
5.1.5. PRECLINICAL MOLECULES
5.1.6. EARLY R&D MOLECULES
5.1.7. INACTIVE AND TERMINATED MOLECULES
5.2. PIPELINE ANALYSIS BY GEOGRAPHY
5.2.1. UNMET NEEDS AND OPPORTUNITIES
5.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
5.3.1. UNMET NEEDS AND OPPORTUNITIES
5.4. PIPELINE ANALYSIS BY DRUG CLASS
5.4.1. UNMET NEEDS AND OPPORTUNITIES
5.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
5.5.1. UNMET NEEDS AND OPPORTUNITIES
5.6 PIPELINE ANALYSIS BY UNIVERSITIES AND INSTITUTES
5.7. ESTIMATED APPROVAL TIMELINES
5.7.1. METHODOLOGY
5.7.2. ESTIMATED APPROVAL TIMELINES US & EX-US
6. MUSCLE INJURY CLINICAL TRIALS SUMMARY
6.1. MUSCLE INJURY PIPELINE ANALYSIS BY CLINICAL TRIALS RESULTS
6.1.1. KEY PHASE 3 RESULTS
6.1.2. KEY PHASE 2 RESULTS
6.2. ONGOING CLINICAL TRIALS SUMMARY
6.2.1. KEY PHASE 3 ONGOING CLINICAL TRIALS SUMMARY
6.2.2. KEY PHASE 2 ONGOING CLINICAL TRIALS SUMMARY
6.2.3. KEY PHASE 1 ONGOING CLINICAL TRIALS SUMMARY
6.3 PLANNED CLINICAL TRIALS SUMMARY
6.4. RECENTLY COMPLETED CLINICAL TRIALS SUMMARY
6.4.1. RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS SUMMARY
6.4.2. RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS SUMMARY
6.4.3. RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS SUMMARY
7. MUSCLE INJURY MARKET BY DRUG CLASS
8. MUSCLE INJURY MARKET BY ROUTE OF ADMINISTRATION
9. MUSCLE INJURY MARKET BY GEOGRAPHY
9.1. UNITED STATES
9.1.1. MARKET TRENDS AND GROWTH FACTORS
9.1.2. UNMET NEEDS AND OPPORTUNITIES
9.1.3. US MUSCLE INJURY MARKET SIZE (2018), FORECAST (2019-2025)
9.2. UNITED KINGDOM
9.2.1. MARKET TRENDS AND GROWTH FACTORS
9.2.2. UNMET NEEDS AND OPPORTUNITIES
9.2.3. UK MUSCLE INJURY MARKET SIZE (2018), FORECAST (2019-2025)
9.3. GERMANY
9.3.1. MARKET TRENDS AND GROWTH FACTORS
9.3.2. GERMANY MUSCLE INJURY MARKET SIZE (2018), FORECAST (2019-2025)
9.4. FRANCE
9.4.1. MARKET TRENDS AND GROWTH FACTORS
9.4.2. UNMET NEEDS AND OPPORTUNITIES
9.4.3. FRANCE MUSCLE INJURY MARKET SIZE (2018), FORECAST (2019-2025)
9.5. ITALY
9.5.1. MARKET TRENDS AND GROWTH FACTORS
9.5.2. UNMET NEEDS AND OPPORTUNITIES
9.5.3. ITALY MUSCLE INJURY MARKET SIZE (2018), FORECAST (2019-2025)
9.6. SPAIN
9.6.1. MARKET TRENDS AND GROWTH FACTORS
9.6.2. UNMET NEEDS AND OPPORTUNITIES
9.6.3. SPAIN MUSCLE INJURY MARKET SIZE (2018), FORECAST (2019-2025)
9.7. JAPAN
9.7.1. MARKET TRENDS AND GROWTH FACTORS
9.7.2. UNMET NEEDS AND OPPORTUNITIES
9.7.3. JAPAN MUSCLE INJURY MARKET SIZE (2018), FORECAST (2019-2025)
9.8. CHINA
9.8.1. MARKET TRENDS AND GROWTH FACTORS
9.8.2. UNMET NEEDS AND OPPORTUNITIES
9.8.3. CHINA MUSCLE INJURY MARKET SIZE (2018), FORECAST (2019-2025)
9.9. INDIA
9.9.1. MARKET TRENDS AND GROWTH FACTORS
9.9.2. UNMET NEEDS AND OPPORTUNITIES
9.9.3. INDIA MUSCLE INJURY MARKET SIZE (2018), FORECAST (2019-2025)
9.10. BRAZIL
9.10.1. MARKET TRENDS AND GROWTH FACTORS
9.10.2. UNMET NEEDS AND OPPORTUNITIES
9.10.3. BRAZIL MUSCLE INJURY MARKET SIZE (2018), FORECAST (2019-2025)
9.11. RUSSIA
9.11.1. MARKET TRENDS AND GROWTH FACTORS
9.11.2. UNMET NEEDS AND OPPORTUNITIES
9.11.3. RUSSIA MUSCLE INJURY MARKET SIZE (2018), FORECAST (2019-2025)
9.12. ROW
9.12.1. MARKET TRENDS AND GROWTH FACTORS
9.12.2. UNMET NEEDS AND OPPORTUNITIES
9.12.3. ROW MARKET SIZE (2018), FORECAST (2019-2025)
10. CURRENT AND FUTURE COMPETITIVE LANDSCAPE
10.1. COMPANIES
10.1.1. ESTABLISHED COMPANY PROFILES WITH SWOT ANALYSIS
10.1.2. TOP 20 EMERGING COMPANIES IN THE MUSCLE INJURY AREA
10.2. UNIVERSITIES AND INSTITUTES
11. ABBREVIATIONS
LIST OF TABLES:
TABLE 1: REPORT HIGHLIGHTS IN NUMERICALS
TABLE 2: LIST OF FDA APPROVED DRUGS FOR MUSCLE INJURY
TABLE 3: LIST OF EMA APPROVED DRUGS FOR MUSCLE INJURY
TABLE 4: MUSCLE INJURY EPIDEMIOLOGY (2018), FORECAST (2019-2025)
TABLE 5: MAJOR ACQUISITIONS AND MERGERS IN MUSCLE INJURY AREA
TABLE 6: MAJOR COLLABORATIVE AGREEMENTS IN MUSCLE INJURY AREA
TABLE 7: MAJOR LICENSING AGREEMENTS IN MUSCLE INJURY AREA
TABLE 8: MAJOR PARTNERSHIPS AND JOINT VENTURE IN MUSCLE INJURY AREA
TABLE 9: MAJOR GRANTS AND FUNDINGS IN MUSCLE INJURY AREA
TABLE 10: MAJOR ALLIANCE DEALS IN MUSCLE INJURY AREA
TABLE 11: US FDA APPROVED DRUGS FOR MUSCLE INJURY SINCE 2010
TABLE 12: EX-US APPROVED DRUGS FOR MUSCLE INJURY SINCE 2010
TABLE 13: PRE-REGISTRATION (FILED) MOLECULES IN THE MUSCLE INJURY DRUG PIPELINE
TABLE 14: PHASE 3 MOLECULES IN THE MUSCLE INJURY DRUG PIPELINE
TABLE 15: PHASE 2 MOLECULES IN THE MUSCLE INJURY DRUG PIPELINE
TABLE 16: PHASE 1 MOLECULES IN THE MUSCLE INJURY DRUG PIPELINE
TABLE 17: PRECLINICAL MOLECULES IN THE MUSCLE INJURY DRUG PIPELINE
TABLE 18: EARLY R&D MOLECULES IN THE MUSCLE INJURY DRUG PIPELINE
TABLE 19: TERMINATED AND INACTIVE MOLECULES IN THE MUSCLE INJURY DRUG PIPELINE
TABLE 20: MUSCLE INJURY DRUG PIPELINE MOLECULES BY ROUTE OF ADMINISTRATION
TABLE 21: MUSCLE INJURY DRUG PIPELINE MOLECULES OVERVIEW BY DRUG CLASS
TABLE 22: MUSCLE INJURY DRUG PIPELINE MOLECULES BY UNIVERSITIES
TABLE 23: MUSCLE INJURY DRUG PIPELINE MOLECULES BY INSTITUTES
TABLE 24: ESTIMATED APPROVAL TIMELINES OF PIPELINE MOLECULES
TABLE 25: KEY PHASE 3 ONGOING CLINICAL TRIALS
TABLE 26: KEY PHASE 2 ONGOING CLINICAL TRIALS
TABLE 27: KEY PHASE 1 ONGOING CLINICAL TRIALS
TABLE 28: PLANNED CLINICAL TRIALS FOR THE MUSCLE INJURY AREA
TABLE 29: RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS
TABLE 30: RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS
TABLE 31: RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS
TABLE 32: GLOBAL MUSCLE INJURY MARKET BY DRUG CLASS (2019-2025)
TABLE 33: GLOBAL MUSCLE INJURY MARKET BY ROA (2019-2025)
TABLE 34: STRENGTH, DOSAGE AND ROA OF MUSCLE INJURY DRUGS
TABLE 35: TOP TEN COUNTRIES/TERRITORIES FOR NUMBER OF NEW CASES OF MUSCLE INJURY PER YEAR
TABLE 36: GLOBAL MUSCLE INJURY MARKET BY GEOGRAPHY, MARKET SIZE (2018), FORECAST (2019-2025)
TABLE 37: US MARKET SIZE (2018), FORECAST (2019-2025)
TABLE 38: UK MARKET SIZE (2018), FORECAST (2019-2025)
TABLE 39: GERMANY MARKET SIZE (2018), FORECAST (2019-2025)
TABLE 40: FRANCE MARKET SIZE (2018), FORECAST (2019-2025)
TABLE 41: ITALY MARKET SIZE (2018), FORECAST (2019-2025)
TABLE 42: SPAIN MARKET SIZE (2018), FORECAST (2019-2025)
TABLE 43: JAPAN MARKET SIZE (2018), FORECAST (2019-2025)
TABLE 44: CHINA MARKET SIZE (2018), FORECAST (2019-2025)
TABLE 45: INDIA MARKET SIZE (2018), FORECAST (2019-2025)
TABLE 46: BRAZIL MARKET SIZE (2018), FORECAST (2019-2025)
TABLE 47: RUSSIA MARKET SIZE (2018), FORECAST (2019-2025)
TABLE 48: ROW MARKET SIZE (2018), FORECAST (2019-2025)
TABLE 49: LIST OF ESTABLISHED COMPANIES IN THE MUSCLE INJURY AREA
TABLE 50: LIST OF EMERGING COMPANIES IN THE MUSCLE INJURY AREA
TABLE 51: COMPETITIVE OPPORTUNITIES, UNIVERSITIES
TABLE 52: COMPETITIVE OPPORTUNITIES, INSTITUTES
(ABOVE MENTIONED TABLES ARE A FEW AMONG THE TOTAL 103 TABLES IN THE REPORT)
LIST OF FIGURES:
FIGURE 1: GLOBAL MUSCLE INJURY MARKET 2019-2025: MARKET SNAPSHOT
FIGURE 2: GLOBAL MUSCLE INJURY MARKET BY GEOGRAPHY 2018 V/S 2025
FIGURE 3: MUSCLE INJURY MARKET BY ROA, 2018
FIGURE 4: MUSCLE INJURY MARKET BY AGE GROUP, 2018
FIGURE 5: KEY INFLECTION POINTS IN MUSCLE INJURY MARKET (2015-2030)
FIGURE 6: MUSCLE INJURY MAJOR FINDINGS
FIGURE 7: MEDICAL EXPENDITURES FOR MUSCLE INJURY
FIGURE 8: MUSCLE INJURY EPIDEMIOLOGY (2018), FORECAST (2019-2025)
FIGURE 9: OVERALL DEALS ACTIVITY IN MUSCLE INJURY AREA
FIGURE 10: GEOGRAPHY WISE BREAK UP V/S DEAL TYPE
FIGURE 11: MUSCLE INJURY DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT
FIGURE 12: MUSCLE INJURY DRUG PIPELINE ANALYSIS BY GEOGRAPHY
FIGURE 13: MUSCLE INJURY DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT V/S GEOGRAPHIES
FIGURE 14: MUSCLE INJURY DRUG PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 15: MUSCLE INJURY DRUG PIPELINE ANALYSIS BY DRUG CLASS
FIGURE 16: ONGOING CLINICAL TRIALS SPLIT-UP BY HSD
FIGURE 17: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY HSD
FIGURE 18: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY MAJOR COMPANIES
FIGURE 19: GRAPHICAL REPRESENTATION OF GLOBAL MUSCLE INJURY MARKET BY DRUG CLASS
FIGURE 20: GRAPHICAL REPRESENTATION OF GLOBAL MUSCLE INJURY MARKET BY ROA
FIGURE 21: GRAPHICAL REPRESENTATION, US MARKET SIZE 2018 V/S 2025
FIGURE 22: GRAPHICAL REPRESENTATION, UK MARKET SIZE 2018 V/S 2025
FIGURE 23: GRAPHICAL REPRESENTATION, GERMANY MARKET SIZE 2018 V/S 2025
FIGURE 24: GRAPHICAL REPRESENTATION, FRANCE MARKET SIZE 2018 V/S 2025
FIGURE 25: GRAPHICAL REPRESENTATION, ITALY MARKET SIZE 2018 V/S 2025
FIGURE 26: GRAPHICAL REPRESENTATION, SPAIN MARKET SIZE 2018 V/S 2025
FIGURE 27: GRAPHICAL REPRESENTATION, JAPAN MARKET SIZE 2018 V/S 2025
FIGURE 28: GRAPHICAL REPRESENTATION, CHINA MARKET SIZE 2018 V/S 2025
FIGURE 29: GRAPHICAL REPRESENTATION, INDIA MARKET SIZE 2018 V/S 2025
FIGURE 30: GRAPHICAL REPRESENTATION, BRAZIL MARKET SIZE 2018 V/S 2025
FIGURE 31: GRAPHICAL REPRESENTATION, RUSSIA MARKET SIZE 2018 V/S 2025
FIGURE 32: GRAPHICAL REPRESENTATION, ROW MARKET SIZE 2018 V/S 2025
FIGURE 33: COMPANY FINANCIAL INFORMATION
FIGURE 34: COMPANY SWOT ANALYSIS
(ABOVE MENTIONED FIGURES ARE A FEW AMONG THE TOTAL 46 FIGURES IN THE REPORT)”